HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) for HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2022 | $1,240,000 | Replaced |
| 2nd Quarter - Amendment | Sep 16, 2022 | $1,240,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act, all provisions. Issues pertaining to the Healthy Futures Task Force, Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. S 909 "Prescription Drug Price Relief Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. HR 19 Lower Costs, More Cures Act of 2021, all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J FISK | — |
| ELI KOGAN | — |
| BETH RADA | — |
Taxation/Internal Revenue Code TAX
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J FISK | — |
| ELI KOGAN | — |
| BETH RADA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.